The present invention features interferon-free therapies for the treatment of HCV. Preferably the treatment is over a shorter duration such as no more than 12 weeks. In one aspect the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example the therapies comprise administering to the subject effective amounts of therapeutic agent 1 therapeutic agent 2 (or therapeutic agent 3) an inhibitor of cytochrome P450 (e.g. rito...

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g...

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1 (ABT) or therapeutic agent 2 (=ABT-...

A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

The present invention relates to a combination of a macrocyclic NS3/4A protease inhibitor of HCV, a HCV NS5B polymerase inhibiting non-nucleoside and ritonavir.

The present invention relates to a novel amorphous Form of lopinavir and ritonavir mixture in the ratio of 3.8:1.2 to 4.2:0.8, process for its preparation and pharmaceutical compositions comprising it.

The present invention relates to a novel amorphous Form of lopinavir and ritonavir mixture in the ratio of 3.8:1.2 to 4.2:0.8 process for its preparation and pharmaceutical compositions comprising it.

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeuti...

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably the treatment is over a shorter duration of treatment such as no more than 12 weeks. In one aspect the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example the therapies comprise administering to a subject an effective amounts of therapeutic agent 1 therapeutic agent 2 (or therapeutic age...